DLA Piper advises ASP Isotopes on Strategic Relationship with PET Labs

DLA Piper advised NASDAQ listed ASP Isotopes, a technology and process developer that produces isotopes for use in multiple industries, on its strategic relationship with PET Labs.

PET Labs is a South African radiopharmaceutical operations company based in Pretoria, dedicated to nuclear medicine and the science of radiopharmaceutical production. It focuses on the production of fluorinated radioisotopes and active pharmaceutical ingredients.

This strategic relationship will help both companies to enhance their company’s growth in the coming years, ensuring a stable supply of PET and SPECT radioisotopes to the markets of Southern Africa and the developing world.

The DLA Piper team was led by Johannesburg-based corporate director André Visser with support from Associate Zama Shoba.

André Visser said: “We are happy to support ASP Isotopes in its strategic relationship with PET Labs in South Africa, in this very specialized area of ​​nuclear medicine. “There is a clear need for additional radioisotope production capacity in the Sub-Saharan Africa and we look forward to supporting both companies as they bring new treatments to patients in frontier markets.”

2 thoughts on “DLA Piper advises ASP Isotopes on Strategic Relationship with PET Labs”

Leave a Comment